Viveve Medical (VIVE) 10-Q 13 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 12, 2016
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	879,682
Trading Symbol	vivmf
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		7,497,857
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	[1]
Current assets:
Cash and cash equivalents	$ 5,006	$ 7,360
Accounts receivable	791	593
Inventory	926	1,549
Prepaid expenses and other current assets	1,542	1,228
Total current assets	8,265	10,730
Property and equipment, net	254	239
Other assets	146	138
Total assets	8,665	11,107
Current liabilities:
Accounts payable	1,629	1,432
Accrued liabilities	2,408	1,293
Note payable	4,192	4,446
Total liabilities	$ 8,229	$ 7,171
Stockholders’ equity:
Preferred stock, no par value; unlimited shares authorized; no shares issued and outstanding as of March 31, 2016 and December 31, 2015
Common stock and paid-in capital, no par value; unlimited shares authorized as of March 31, 2016 and December 31, 2015; 7,497,857 and 7,490,288 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	$ 53,053	$ 52,447
Accumulated deficit	(52,617)	(48,511)
Total stockholders’ equity	436	3,936
Total liabilities and stockholders’ equity	$ 8,665	$ 11,107
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2016	Dec. 31, 2015	[1]
Preferred Stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares issued (in shares)	7,497,857	7,490,288
Common stock, shares outstanding (in shares)	7,497,857	7,490,288
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue	$ 1,284	$ 38
Cost of revenue	936	50
Gross profit (loss)	348	(12)
Operating expenses:
Research and development	1,796	845
Selling, general and administrative	2,548	1,577
Total operating expenses	4,344	2,422
Loss from operations	(3,996)	(2,434)
Interest expense	(108)	(83)
Other expense, net	(2)	(7)
Comprehensive and net loss	$ (4,106)	$ (2,524)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.55)	$ (1.10)
Weighted average shares used in computing net loss per common share
Basic and diluted (in shares)	7,493,011	2,293,057

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016		Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (4,106)		$ (2,524)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	21		17
Stock-based compensation	188		42
Fair value of warrants issued	142		262
Non-cash interest expense	45		48
Changes in assets and liabilities:
Accounts receivable	(198)		(29)
Inventory	623		(36)
Prepaid expenses and other current assets	(314)		(6)
Other noncurrent assets	(8)		(4)
Accounts payable	197		196
Accrued liabilities	1,361		360
Net cash used in operating activities	(2,049)		$ (1,674)
Cash flows from investing activities:
Proceeds from sale of property and equipment	1
Purchases of property and equipment	(37)
Net cash used in investing activities	$ (36)
Cash flows from financing activities:
Proceeds from note payable			$ 1,000
Repayments of notes payable	$ (299)
Transaction costs in connection with November 2015 Offering	(3)
Proceeds from exercise of warrant	27
Proceeds from exercise of stock option	6
Net cash (used in) provided by financing activities	(269)		$ 1,000
Net decrease in cash and cash equivalents	(2,354)		(674)
Cash and cash equivalents - beginning of period	7,360	[1]	895
Cash and cash equivalents - end of period	5,006		221
Supplemental disclosure:
Cash paid for interest	$ 64		35
Cash paid for income taxes			$ 1
Supplemental disclosure of cash flow information as of end of period:
Restricted stock awards granted to employees for 2015 accrued bonuses	$ 246
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been derived from the audited consolidated financial statements as of that date.

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s health industry by marketing the Viveve System™ as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal laxity. Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the condensed consolidated financial statements have been included. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on March 24, 2016.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. Accounting Standards Update (“ASU”) 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for the Company’s fiscal year beginning January 1, 2016. We have adopted this guidance in the first quarter of 2016. Accordingly, the Company has revised the classification in the condensed consolidated balance sheet to report debt issuance costs as a contra debt liability as of December 31, 2015. This resulted in a decrease of $387,000 to the December 31, 2015 amounts reported as prepaid expenses and other current assets, total assets, note payable, total liabilities, and total liabilities and stockholders’ equity. Reverse Stock Split On April 15, 2016, the Company effected a 1-for-8 reverse stock split of its common stock. On the effective date of the reverse stock split, (i) each 8 shares of outstanding common stock were reduced to one share of common stock; (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable were proportionately reduced on an 8-to-1 basis; and (iii) the exercise price of each outstanding warrant or option to purchase common stock were proportionately increased on a 1-to-8 basis. All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1-for-8 reverse stock split. Use of Estimates The preparation of condensed consolidated financial statements in conformity with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results. Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company’s products may require approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s products will receive any of these required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse effect on the Company’s financial results, financial position and future cash flows. The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company outsources the manufacture and repair of the Viveve System to a single contract manufacturer. Also, certain other components and materials that comprise the Viveve System are currently manufactured by a single supplier or a limited number of suppliers. A significant supply interruption or disruption in the operations of the contract manufacturer or these third-party suppliers would adversely impact the production of our products for a substantial period of time, which could have a material adverse effect on our business, financial condition, operating results and cash flows. During the three months ended March 31, 2016, three customers accounted for 86% of the Company’s revenue. During the three months ended March 31, 2015, one customer accounted for 93% of the Company’s revenue. Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance outside the U.S. and currently sells the Viveve System in Canada, Hong Kong, Japan, Europe, the Middle East and Southeast Asia. The Company does not provide its customers with a contractual right of return. Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities and revenue is recognized upon shipment of the product assuming all other revenue recognition criteria are met. Product Warranty The Company’s products are generally subject to a one-year warranty, which provides for the repair, rework or replacement of products (at the Company’ option) that fail to perform within stated specification. The Company has assessed the historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess the need to record a warranty accrual at the time of sale going forward. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended March 31, 2016 and 2015, the Company’s comprehensive loss is the same as its net loss. Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, warrants to purchase common stock, stock options and rights to common stock are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Three Months Ended March 31, 2016 2015 Stock options to purchase common stock 1,131,768 363,252 Warrants to purchase common stock 401,446 301,399 Rights to common stock - 70,755 Recently Issued and Adopted Accounting Standards In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual and interim periods beginning after December 15, 2017. We are currently evaluating the impact that this standard will have on our condensed consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently evaluating the effect of the adoption of this guidance on our condensed consolidated financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for the Company’s fiscal year beginning January 1, 2016 and subsequent interim periods, with earlier adoption permitted. We have adopted this guidance in the first quarter of 2016 and have reclassified our balance sheet to comply with the new standard. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” (“ASU 2015-11”). ASU 2015-11 requires that an entity should measure inventory within the scope of this pronouncement at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The pronouncement does not apply to inventory that is being measured using the last-in, first-out (“LIFO”) method or the retail inventory method. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. ASU 2015-11 will be effective for the Company’s fiscal year beginning January 1, 2017 and subsequent interim periods, with earlier adoption permitted. We are currently evaluating the effect of the adoption of this guidance on our condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. Under this guidance, an entity is required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within the reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the effect of the adoption of this guidance on its financial statements. In March 2016, the FASB issued ASU 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This guidance identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within the reporting period, with early adoption permitted. The Company is currently evaluating the effect of the adoption of this guidance on its financial statements.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult. Level 2 Pricing is provided by third party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors. Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no financial instruments that were measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of March 31, 2016 and December 31, 2015 approximate fair value because of the short maturity of these instruments. Based on borrowing rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair value.

Note 4 - Accrued Liabilities

Note 4 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): March 31, December 31, 2016 2015 Customer advance payments $ 1,418 $ 20 Accrued professional fees 432 388 Accrued bonuses 164 613 Accrued vacation 121 68 Accrued clinical trial costs 89 112 Other accruals 184 92 Total accrued liabilities $ 2,408 $ 1,293

Note 5 - Note Payable

Note 5 - Note Payable	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	5. Note Payable On September 30, 2014, we entered into a Loan and Security Agreement, as amended on February 19, 2015, May 14, 2015, November 30, 2015 and March 18, 2016 (collectively, the “Loan Agreement”), with Pacific Western Bank (as successor in interest by merger to Square 1 Bank) (the “Lender”) pursuant to which we received a term loan in the amount of $5.0 million, funded in 3 tranches. The first tranche of $2.5 million was provided to us on October 1, 2014 and proceeds of $500,000 from the second tranche were received on each of February 19, 2015, March 16, 2015 and April 6, 2015 for aggregate proceeds of $1,500,000. The first tranche borrowing is repayable in interest only payments until November 1, 2015 and then 30 equal monthly installments of principal and interest at a rate of 5.25% per annum. The second tranche borrowings in February, March and April 2015 are repayable in interest only payments until March 1, 2016 and then 30 monthly equal installments of principal and interest at a rate of 5.00%, 5.06% and 5.00% per annum, respectively. The terms of the loan also require that the Company meet certain financial covenants and milestones in connection with the Company’s randomized, blinded and sham-controlled clinical trial in Europe and Canada (the “OUS Clinical Trial”), including, but not limited to, (a) full enrollment as of March 31, 2015, (b) positive 3-month interim data as of July 10, 2015, and (c) positive results from the trial as of January 31, 2016. Full enrollment of the OUS Clinical Trial was achieved prior to March 31, 2015. Additionally, the Company provided evidence to the lender of positive three month interim results with respect to the OUS Clinical Trial, and on July 15, 2015 we received the final $1,000,000 of the term loan with a drawdown of funds from the third tranche. The third tranche borrowing is repayable in interest only payments until August 1, 2016 and then 30 equal monthly installments of principal and interest at a rate of 6.56% per annum. While we were able to provide evidence of positive 3-month interim data as of July 10, 2015, due to over-enrollment of the OUS Clinical Trial we were unable to provide positive results as of January 31, 2016 and we were not in compliance, as of February 18, 2016, of a covenant requiring us to keep a minimum cash balance at the Lender’s institution (the “Covenant Failures”). On March 18, 2016, we entered into the Fourth Amendment to the Loan and Security Agreement pursuant to which the Lender waived the Covenant Failures. The Fourth Amendment also extended the date, to April 30, 2016, of the requirement that we provide evidence of positive results from the OUS Clinical Trial and revised the minimum cash balance requirement. Following execution of the Fourth Amendment, we must maintain a balance of cash of at least $3,000,000 at the Lender’s institution. As of March 31, 2016, the Company was in compliance with all covenants of the Loan Agreement. As of March 31, 2016 and December 31, 2015, the note payable had an outstanding net loan balance of $4.2 million and $4.4 million, respectively, which is recorded as a current liability on the condensed consolidated balance sheets. All borrowings under the Loan Agreement are collateralized by substantially all of the Company’s assets, including intellectual property. In connection with the Loan Agreement, the Company issued a 10-year warrant to the lender for the purchase of 58,962 shares of the Company’s common stock at $4.24 per share. In connection with the first loan amendment in February 2015, the Company also amended the terms of the warrant issued to the lender to provide for an automatic increase of the number of shares the lender may acquire in the event the Company fails to meet certain covenants. In connection with the second loan amendment in May 2015, the Company issued a second 10-year warrant to the lender to purchase a total of 3,125 shares of common stock at an exercise price of $2.96 per share. (See Note 7.) The Loan Agreement with the financial institution contains a material adverse change clause, as defined in the Loan Agreement, which would result in an event of default if the lender deems a material adverse change to have occurred to the Company’s business. The continuing liquidity issues the Company faces could be construed by the lender (or any subsequent note holder) as a material adverse change which could trigger an acceleration of all of the outstanding debt. As such, the Company has classified all of its outstanding debt balance as a current liability as of March 31, 2016 and December 31, 2015. As of March 31, 2016, future minimum payments under the note payable are as follows (in thousands): Year Ending December 31, 2016 (remaining 9 months) $ 1,530 2017 2,124 2018 1,161 2019 34 Total payments 4,849 Less: Amount representing interest (315 ) Present value of obligations 4,534 Less: Unamortized debt discount (342 ) 4,192 Less: Notes payable, current portion 4,192 Note payable, noncurrent portion $ -

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6. Commitments and Contingencies Operating Lease In January 2012, the Company entered into a lease agreement for office and laboratory facilities. The lease agreement, as amended in January 2015, commenced in March 2012 and will terminate in March 2017. Rent expense for the three months ended March 31, 2016 and 2015 was $55,000 and $47,000, respectively. As of March 31, 2016, future minimum payments under the lease are as follows (in thousands): Year Ending December 31, 2016 ( remaining 9 months) $ 173 2017 58 Total minimum lease payments $ 231 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not breached the agreement and/or the loss is not attributable to the indemnified party’s negligence or willful malfeasance. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding in considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates, which could materially impact its condensed consolidated financial statements.

Note 7 - Common Stock

Note 7 - Common Stock	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. Common Stock Warrants for Common Stock As of March 31, 2016, outstanding warrants to purchase an aggregate of 401,446 shares of common stock were as follows: Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 110,550 September 2014 Common Shares September 30, 2024 $ 4.24 58,962 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 October 2014 Common Shares October 31, 2019 $ 4.24 469 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 14, 2025 $ 2.96 3,125 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 March 2016 Common Shares March 31, 2026 $ 6.08 25,000 401,446 In connection with a private offering that closed on September 30, 2014, the Company issued warrants to purchase a total of 117,535 shares of common stock at an exercise price of $4.24 per share. The warrants have a contractual life of five years and are exercisable immediately in whole or in part, on or before five years from the issuance date. A total of 735 and 6,250 shares issuable pursuant to these warrants were exercised in 2015 and March 2016, respectively. In connection with the Loan Agreement entered into on September 30, 2014, the Company issued a warrant to purchase a total of 58,962 shares of common stock at an exercise price of $4.24 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The fair value of the warrant was recorded as debt issuance costs, presented in the condensed consolidated balance sheets as a deduction from the carrying amount of the note payable, and will be amortized to interest expense over the loan term. During the three months ended March 31, 2016 and 2015, the Company recorded $45,000 and $48,000, respectively, of interest expense relating to the debt issuance costs. As of March 31, 2016, the remaining unamortized debt issuance costs were $342,000 and the warrant remained outstanding. In connection with the first loan amendment in February 2015, the Company also amended the terms of the warrant issued to the lender to provide for an automatic increase of the number of shares the lender may acquire in the event the Company fails to meet certain covenants to achieve certain OUS Clinical Trial milestones or capital raising requirements as set forth in the Loan Agreement, as amended, by a number equal to the quotient derived by dividing (i) 1% of the principal balance outstanding under the Loan Agreement by (ii) the exercise price of $4.24 per share. In October and November of 2014, the Company issued common stock warrants to various vendors and nonemployee contractors to purchase a total of 47,751 shares of common stock at an exercise price of $4.24 per share. The warrants have a contractual life of five years and are exercisable in whole or in part, either immediately upon grant or in some cases upon achieving certain milestones or vesting terms. The fair values of the warrants were recorded as professional consulting fees or clinical costs, which are included in selling, general and administrative and research and development expenses in the consolidated statements of operations for the year ended December 31, 2014, depending on the nature of the services provided. Stock-based compensation expense related to these warrants is recognized as the warrants are earned and was zero and $15,000 for the three months ended March 31, 2016 and 2015, respectively. A total of 5,157 and 625 shares issuable pursuant to warrants issued to two vendors in October 2014 were cancelled in 2015 and March 2016, respectively, as the milestones related to these shares were not achieved. In February 2015, the Company issued to employees for performance bonuses common stock warrants to purchase a total of 75,697 shares of common stock at an exercise price of $4.00 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The fair values of the warrants were recorded in selling, general and administrative and research and development expenses in the condensed consolidated statements of operations for the three months ended March 31, 2015, depending on the department classification of the employee. The Company recorded zero and $244,000 of stock-based compensation expense related to these warrants in the three months ended March 31, 2016 and 2015, respectively. In March 2015, the Company issued a common stock warrant to a nonemployee contractor to purchase a total of 1,454 shares of common stock at an exercise price of $2.72 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The fair value of the warrant was recorded as professional consulting fees, which are included in selling, general and administrative expenses in the condensed consolidated statements of operations for the three months ended March 31, 2015. The Company recorded zero and $3,000 of stock-based compensation expense related to these warrants in the three months ended March 31, 2016 and 2015, respectively. In May 2015, the Company issued common stock warrants to nonemployee contractors to purchase a total of 36,229 shares of common stock at an exercise price of $4.24 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The fair values of the warrants were recorded as professional consulting fees, which are included in selling, general and administrative expenses in the condensed consolidated statements of operations for the three months ended June 30, 2015. Stock-based compensation expense related to these warrants was zero for both the three months ended March 31, 2016 and 2015. In conjunction with the second loan amendment in May 2015, the Company issued a warrant to the lender to purchase a total of 3,125 shares of common stock at an exercise price of $2.96 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The fair value of the warrant was recorded as debt issuance costs, and was amortized to interest expense over the period from the date of issuance to the end of the extended period to draw down the additional funds in connection with the third tranche or July 15, 2015. During the three months ended March 31, 2016 and 2015, the Company recorded zero of interest expense relating to the debt issuance costs for this warrant. As of March 31, 2016, the remaining unamortized debt issuance costs were zero. In May 2015, the Company issued a common stock warrant to a nonemployee contractor to purchase a total of 21,585 shares of common stock at an exercise price of $4.24 per share. The warrant has a contractual life of five years and is exercisable immediately in whole or in part, on or before five years from the issuance date. The fair value of the warrant was recorded as professional consulting fees, which are included in selling, general and administrative expenses in the condensed consolidated statements of operations. Stock-based compensation expense related to these warrants was zero for both the three months ended March 31, 2016 and 2015. In December 2015, the Company issued common stock warrants to employees and nonemployee contractors for performance bonuses to purchase a total of 26,875 shares of common stock at an exercise price of $5.60 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The fair values of the warrants were recorded in selling, general and administrative and research and development expenses in the consolidated statements of operations, depending on the department classification of the employee or nonemployee contractor. The stock-based compensation expense related to these warrants was zero for both the three months ended March 31, 2016 and 2015. In March 2016, the Company issued a common stock warrant to a distributor to purchase a total of 25,000 shares of common stock at an exercise price of $6.08 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrant using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 72.1%, risk free interest rate of 1.78% and a contractual life of ten years. The Company recorded $142,000 of stock-based compensation expense related to these warrants in the three months ended March 31, 2016.

Note 8 - Summary of Stock Optio

Note 8 - Summary of Stock Options	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options from three employee benefit plans. The plans include the Company’s 2005 Stock Incentive Plan (the “2005 Plan”), the Viveve Amended and Restated 2006 Stock Plan (the “2006 Plan”) and the Company’s 2013 Stock Option and Incentive Plan, as amended (the “2013 Plan”). The 2005 Plan was adopted by the Company’s board of directors and approved by its stockholders. As of March 31, 2016, 2,778 shares of common stock remain reserved for issuance under the 2005 Plan. The Company does not intend to grant further awards from the 2005 Plan, however, it will continue to administer the 2005 Plan until all outstanding awards are exercised, expire, terminate or are forfeited. There are currently outstanding stock option awards issued from the 2005 Plan covering a total of 2,778 shares of the Company’s common stock. The weighted average exercise price of the outstanding stock options is $102.68 per share and the weighted average remaining contractual term is 1.36 years. The 2006 Plan was adopted by the board of directors of Viveve, Inc. and was terminated in conjunction with the merger that took place on September 23, 2014 between PLC Systems Inc., Viveve, Inc. and PLC Systems Acquisition Corp. (the “Merger”). Prior to the Merger, the board of directors voted to accelerate the vesting of all unvested options that were outstanding as of the date of the Merger such that all options would be immediately vested and exercisable by the holders. In conjunction with the Merger, the Company agreed to assume and administer the 2006 Plan and all outstanding options to purchase shares of Viveve, Inc. common stock issued from the 2006 Plan were converted into options to purchase shares of the Company’s common stock (rounded down to the nearest whole share). The number of shares of the Company’s common stock into which the 2006 Plan options were converted was determined by multiplying the number of shares covered by each 2006 Plan option by the exchange ratio of 0.0080497 (or .0010062 on a post- reverse stock split basis). The exercise price of each 2006 Plan option was determined by dividing the exercise price of each 2006 Plan option immediately prior to the Merger by the exchange ratio of 0.0080497 (or .0010062 on a post- reverse stock split basis) (rounded up to the nearest cent). There are currently outstanding stock option awards issued from the 2006 Plan covering a total of 39,024 shares of the Company’s common stock and no shares are available for future awards. The weighted average exercise price of the outstanding stock options is $11.10 per share and the weighted average remaining contractual term is 6.53 years. The 2013 Plan was also adopted by the Company’s board of directors and approved by its stockholders. The 2013 Plan is administered by the Compensation Committee of the Company’s board of directors (the “Administrator”). Under the 2013 Plan, the Company may grant equity awards to eligible participants which may take the form of stock options (both incentive stock options and non-qualified stock options), stock appreciation rights, restricted, deferred or unrestricted stock awards, performance based awards or dividend equivalent rights. Awards may be granted to officers, employees, nonemployee directors (as defined in the 2013 Plan) and other key persons (including consultants and prospective employees). The term of any stock option award may not exceed 10 years and may be subject to vesting conditions, as determined by the Administrator. Options granted generally vest over four years. Incentive stock options may be granted only to employees of the Company or any subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Internal Revenue Code. The exercise price of any stock option award cannot be less than the fair market value of the Company’s common stock, provided, however, that an incentive stock option granted to an employee who owns more than 10% of the Company’s outstanding voting power must have an exercise price of no less than 110% of the fair market value of the Company’s common stock and a term that does not exceed five years. On July 22, 2015, the Company’s stockholders approved an amendment to the 2013 Plan increasing the number of shares of common stock authorized for awards under the 2013 Plan from 388,949 shares to a total of 1,262,500 shares. As of March 31, 2016, there are outstanding stock option awards issued from the 2013 Plan covering a total of 1,089,966 shares of the Company’s common stock and there remain reserved for future awards 130,918 shares of the Company’s common stock. The weighted average exercise price of the outstanding stock options is $6.01 per share, and the remaining contractual term is 9.36 years. Activity under the 2005 Plan, the 2006 Plan and the 2013 Plan is as follows: Three Months Ended March 31, 2016 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,022,195 $ 6.47 9.37 $ - Options granted 129,267 $ 6.35 Options exercised (1,314 ) $ 4.80 Options canceled (18,380 ) $ 8.55 Options outstanding, end of period 1,131,768 $ 6.42 9.24 $ 414,727 Vested and exercisable and expected to vest, end of period 1,035,338 $ 6.48 9.22 $ 392,137 Vested and exercisable, end of period 179,832 $ 9.86 7.90 $ 125,415 The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of March 31, 2016. The options outstanding and exercisable as of March 31, 2016 are as follows: Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2016 Price Term (Years) March 31, 2016 Price $2.64 12,500 $ 2.64 9.12 - $ - $3.68 - $3.76 79,376 $ 3.75 8.86 21,498 $ 3.75 $4.80 212,300 $ 4.80 8.43 81,288 $ 4.80 $6.00 609,003 $ 6.00 9.72 29,599 $ 6.00 $6.24 - $6.40 129,267 $ 6.35 9.91 - $ - $7.12 - $7.92 41,875 $ 7.67 9.35 - $ - $9.92 38,429 $ 9.92 6.59 38,429 $ 9.92 $56.00 - $72.00 6,810 $ 69.63 1.42 6,810 $ 69.63 $96.00 - $149.04 2,176 $ 119.53 1.49 2,176 $ 119.53 $296.00 32 $ 296.00 1.48 32 $ 296.00 1,131,768 $ 6.42 9.24 179,832 $ 9.86 Stock-Based Compensation During the three months ended March 31, 2016 and 2015, the Company granted stock options to employees to purchase 129,267 and 79,375 shares of common stock with a weighted average grant date fair value of $3.56 and $2.00 per share, respectively. Stock-based compensation expense recognized during the three months ended March 31, 2016 and 2015 was $188,000 and $42,000, respectively. As of March 31, 2016, the total unrecognized compensation cost in connection with unvested stock options was approximately $2,598,000. These costs are expected to be recognized over a period of approximately 3.50 years. The aggregate intrinsic value of options exercised during the three months ended March 31, 2016 and 2015 was $2,000 and $0 respectively. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following assumptions: Three Months Ended March 31 2016 2015 Expected term (in years) 5 5 Average volatility 66 % 62 % Risk-free interest rate 1.55 % 1.32 % Dividend yield 0 % 0 % Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No dividend yield is included as the Company has not issued any dividends and does not anticipate issuing any dividends in the future. The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 (in thousands): Three Months Ended March 31, 2016 2015 Research and development $ 21 $ 4 Selling, general and administrative 167 38 Total $ 188 $ 42

Note 9 - Income Taxes

Note 9 - Income Taxes	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. Income Taxes Provision for Income Tax For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% for the three months ended March 31, 2016 and 2015. The Company expects that its effective tax rate for the full year 2016 will be 0%.

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	10. Related Party Transactions In June 2006, the Company entered into a Development and Manufacturing Agreement with Stellartech Research Corporation (the “Agreement”). The Agreement was amended on October 4, 2007. Under the Agreement, the Company agreed to purchase 300 generators manufactured by Stellartech. As of March 31, 2016, the Company has purchased 113 units. The price per unit is variable and dependent on the volume and timing of units ordered. In conjunction with the Agreement, Stellartech purchased 37,500 shares of Viveve’s common stock. These shares are subject to a right of repurchase by the Company, which lapses over a four-year period. As of March 31, 2016, none of the shares of common stock were subject to repurchase. Under the Agreement, the Company paid Stellartech $1,215,000 and $129,000 for goods and services during the three months ended March 31, 2016 and 2015, respectively.

Note 11 - Subsequent Events

Note 11 - Subsequent Events	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	11. Subsequent Events On April 15, 2016, we effected a 1-for-8 reverse split of our common stock and common stock equivalents. On April 21, 2016, the Company announced positive top line results from the OUS Clinical Trial providing evidence to our lender that positive results were achieved with respect to the OUS Clinical Trial prior to the loan covenant requirement date of April 30, 2016. On May 9, 2016, the Company filed the necessary Application for Authorization to Continue into Another Jurisdiction and Statutory Declaration with the Yukon registrar. On May 10, 2016, the Company filed a Certificate of Conversion and Certificate of Incorporation with the Secretary of State of the State of Delaware to move its domicile from the Yukon Territory to Delaware.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Reclassification, Policy [Policy Text Block]	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. Accounting Standards Update (“ASU”) 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for the Company’s fiscal year beginning January 1, 2016. We have adopted this guidance in the first quarter of 2016. Accordingly, the Company has revised the classification in the condensed consolidated balance sheet to report debt issuance costs as a contra debt liability as of December 31, 2015. This resulted in a decrease of $387,000 to the December 31, 2015 amounts reported as prepaid expenses and other current assets, total assets, note payable, total liabilities, and total liabilities and stockholders’ equity.
Stockholders' Equity, Policy [Policy Text Block]	Reverse Stock Split On April 15, 2016, the Company effected a 1-for-8 reverse stock split of its common stock. On the effective date of the reverse stock split, (i) each 8 shares of outstanding common stock were reduced to one share of common stock; (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable were proportionately reduced on an 8-to-1 basis; and (iii) the exercise price of each outstanding warrant or option to purchase common stock were proportionately increased on a 1-to-8 basis. All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1-for-8 reverse stock split.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company’s products may require approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s products will receive any of these required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse effect on the Company’s financial results, financial position and future cash flows. The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company outsources the manufacture and repair of the Viveve System to a single contract manufacturer. Also, certain other components and materials that comprise the Viveve System are currently manufactured by a single supplier or a limited number of suppliers. A significant supply interruption or disruption in the operations of the contract manufacturer or these third-party suppliers would adversely impact the production of our products for a substantial period of time, which could have a material adverse effect on our business, financial condition, operating results and cash flows. During the three months ended March 31, 2016, three customers accounted for 86% of the Company’s revenue. During the three months ended March 31, 2015, one customer accounted for 93% of the Company’s revenue.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance outside the U.S. and currently sells the Viveve System in Canada, Hong Kong, Japan, Europe, the Middle East and Southeast Asia. The Company does not provide its customers with a contractual right of return.
Customer Advance Payments, Policy [Policy Text Block]	Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities and revenue is recognized upon shipment of the product assuming all other revenue recognition criteria are met.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to a one-year warranty, which provides for the repair, rework or replacement of products (at the Company’ option) that fail to perform within stated specification. The Company has assessed the historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess the need to record a warranty accrual at the time of sale going forward.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended March 31, 2016 and 2015, the Company’s comprehensive loss is the same as its net loss.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, warrants to purchase common stock, stock options and rights to common stock are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Three Months Ended March 31, 2016 2015 Stock options to purchase common stock 1,131,768 363,252 Warrants to purchase common stock 401,446 301,399 Rights to common stock - 70,755
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual and interim periods beginning after December 15, 2017. We are currently evaluating the impact that this standard will have on our condensed consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently evaluating the effect of the adoption of this guidance on our condensed consolidated financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for the Company’s fiscal year beginning January 1, 2016 and subsequent interim periods, with earlier adoption permitted. We have adopted this guidance in the first quarter of 2016 and have reclassified our balance sheet to comply with the new standard. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” (“ASU 2015-11”). ASU 2015-11 requires that an entity should measure inventory within the scope of this pronouncement at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The pronouncement does not apply to inventory that is being measured using the last-in, first-out (“LIFO”) method or the retail inventory method. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. ASU 2015-11 will be effective for the Company’s fiscal year beginning January 1, 2017 and subsequent interim periods, with earlier adoption permitted. We are currently evaluating the effect of the adoption of this guidance on our condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. Under this guidance, an entity is required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within the reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the effect of the adoption of this guidance on its financial statements. In March 2016, the FASB issued ASU 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This guidance identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within the reporting period, with early adoption permitted. The Company is currently evaluating the effect of the adoption of this guidance on its financial statements.

Note 2 - Summary of Significa18

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2016 2015 Stock options to purchase common stock 1,131,768 363,252 Warrants to purchase common stock 401,446 301,399 Rights to common stock - 70,755

Note 4 - Accrued Liabilities (T

Note 4 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2016 2015 Customer advance payments $ 1,418 $ 20 Accrued professional fees 432 388 Accrued bonuses 164 613 Accrued vacation 121 68 Accrued clinical trial costs 89 112 Other accruals 184 92 Total accrued liabilities $ 2,408 $ 1,293

Note 5 - Note Payable (Tables)

Note 5 - Note Payable (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2016 (remaining 9 months) $ 1,530 2017 2,124 2018 1,161 2019 34 Total payments 4,849 Less: Amount representing interest (315 ) Present value of obligations 4,534 Less: Unamortized debt discount (342 ) 4,192 Less: Notes payable, current portion 4,192 Note payable, noncurrent portion $ -

Note 6 - Commitments and Cont21

Note 6 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2016 ( remaining 9 months) $ 173 2017 58 Total minimum lease payments $ 231

Note 7 - Common Stock (Tables)

Note 7 - Common Stock (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 110,550 September 2014 Common Shares September 30, 2024 $ 4.24 58,962 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 October 2014 Common Shares October 31, 2019 $ 4.24 469 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 14, 2025 $ 2.96 3,125 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 March 2016 Common Shares March 31, 2026 $ 6.08 25,000 401,446

Note 8 - Summary of Stock Opt23

Note 8 - Summary of Stock Options (Tables)	3 Months Ended
	Mar. 31, 2016
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Three Months Ended March 31, 2016 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,022,195 $ 6.47 9.37 $ - Options granted 129,267 $ 6.35 Options exercised (1,314 ) $ 4.80 Options canceled (18,380 ) $ 8.55 Options outstanding, end of period 1,131,768 $ 6.42 9.24 $ 414,727 Vested and exercisable and expected to vest, end of period 1,035,338 $ 6.48 9.22 $ 392,137 Vested and exercisable, end of period 179,832 $ 9.86 7.90 $ 125,415
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2016 Price Term (Years) March 31, 2016 Price $2.64 12,500 $ 2.64 9.12 - $ - $3.68 - $3.76 79,376 $ 3.75 8.86 21,498 $ 3.75 $4.80 212,300 $ 4.80 8.43 81,288 $ 4.80 $6.00 609,003 $ 6.00 9.72 29,599 $ 6.00 $6.24 - $6.40 129,267 $ 6.35 9.91 - $ - $7.12 - $7.92 41,875 $ 7.67 9.35 - $ - $9.92 38,429 $ 9.92 6.59 38,429 $ 9.92 $56.00 - $72.00 6,810 $ 69.63 1.42 6,810 $ 69.63 $96.00 - $149.04 2,176 $ 119.53 1.49 2,176 $ 119.53 $296.00 32 $ 296.00 1.48 32 $ 296.00 1,131,768 $ 6.42 9.24 179,832 $ 9.86
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31 2016 2015 Expected term (in years) 5 5 Average volatility 66 % 62 % Risk-free interest rate 1.55 % 1.32 % Dividend yield 0 % 0 %
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended March 31, 2016 2015 Research and development $ 21 $ 4 Selling, general and administrative 167 38 Total $ 188 $ 42

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Apr. 15, 2016	Mar. 31, 2016USD ($)	Mar. 31, 2015
Reclassification to Report Debt Issuance Costs as a Contra Debt Liability [Member] | December 31, 2015 [Member]
Prior Period Reclassification Adjustment		$ (387,000)
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	8
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]
Concentration Risk, Percentage		86.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Concentration Risk, Percentage			93.00%
Warranty Period		1 year

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	1,131,768	363,252
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	401,446	301,399
Rights to Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		70,755

Note 4 - Accrued Liabilities -

Note 4 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Customer advance payments	$ 1,418	$ 20
Accrued professional fees	432	388
Accrued bonuses	164	613
Accrued vacation	121	68
Accrued clinical trial costs	89	112
Other accruals	184	92
Total accrued liabilities	$ 2,408	$ 1,293	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been derived from the audited consolidated financial statements as of that date.

Note 5 - Note Payable (Details

Note 5 - Note Payable (Details Textual)	Jul. 15, 2015USD ($)	Apr. 06, 2015USD ($)	Mar. 16, 2015USD ($)	Feb. 19, 2015USD ($)	Oct. 02, 2014USD ($)	May. 31, 2015$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares	Apr. 06, 2015	Mar. 31, 2016USD ($)shares	Mar. 18, 2016USD ($)	Dec. 31, 2015USD ($)		Feb. 28, 2015$ / sharesshares	Nov. 30, 2014$ / sharesshares
September 2014 Term Loan [Member] | Second Tranche [Member]
Proceeds from Loans		$ 500,000	$ 500,000	$ 500,000
Debt Instrument, Face Amount							$ 1,500,000
Debt Instrument Repayment Of Principal And Interest Number Of Installments								30
Debt Instrument, Interest Rate, Stated Percentage		5.00%	5.06%	5.00%				5.00%
September 2014 Term Loan [Member] | First Tranche [Member]
Proceeds from Loans					$ 2,500,000
Debt Instrument Repayment Of Principal And Interest Number Of Installments					30
Debt Instrument, Interest Rate, Stated Percentage					5.25%
September 2014 Term Loan [Member] | Third Tranche [Member]
Proceeds from Loans	$ 1,000,000
Debt Instrument Repayment Of Principal And Interest Number Of Installments	30
Debt Instrument, Interest Rate, Stated Percentage							6.56%
September 2014 Term Loan [Member]
Debt Instrument, Face Amount							$ 5,000,000
Minimum Cash Balance Requirement										$ 3,000,000
Notes Payable, Current									$ 4,200,000		$ 4,400,000
Warrant Term						10 years	10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						3,125	58,962
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 2.96	$ 4.24
Notes Payable, Current									$ 4,192,000		$ 4,446,000	[1]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares									401,446				75,697	47,751
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 4	$ 4.24
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been derived from the audited consolidated financial statements as of that date.

Note 5 - Note Payable - Summary

Note 5 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	[1]
2016 (remaining 9 months)	$ 1,530
2,017	2,124
2,018	1,161
2,019	34
Total payments	4,849
Less: Amount representing interest	(315)
Present value of obligations	4,534
Less: Unamortized debt discount	(342)
	4,192
Notes Payable, Current	$ 4,192	$ 4,446
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Commitments and Cont29

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating Leases, Rent Expense	$ 55,000	$ 47,000

Note 6 - Commitments and Cont30

Note 6 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2016USD ($)
2016 ( remaining 9 months)	$ 173
2,017	58
Total minimum lease payments	$ 231

Note 7 - Common Stock (Details

Note 7 - Common Stock (Details Textual) - USD ($)	1 Months Ended				3 Months Ended		12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	May. 31, 2015	Sep. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	May. 30, 2015	Feb. 28, 2015	Nov. 30, 2014
May 2015 Issuance [Member]
Allocated Share-based Compensation Expense					$ 0	$ 0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			36,229
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4.24
Fair Value Assumptions, Expected Term			10 years
March 2015 Issuance [Member]
Allocated Share-based Compensation Expense					0	$ 3,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						1,454
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 2.72
May 2015 Issuance Second Contractor [Member]
Allocated Share-based Compensation Expense					0	$ 0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								21,585
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 4.24
Fair Value Assumptions, Expected Term			5 years
December 2015 Issuance [Member]
Allocated Share-based Compensation Expense					0	0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		26,875					26,875
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.60					$ 5.60
Warrant Term		10 years
March 2016 Issuance [Member]
Allocated Share-based Compensation Expense					$ 142,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	25,000				25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.08				$ 6.08
Warrant Term					10 years
Fair Value Assumptions, Expected Dividend Rate					0.00%
Fair Value Assumptions, Expected Volatility Rate					72.10%
Fair Value Assumptions, Risk Free Interest Rate					1.78%
Private Placement [Member]
Class of Warrant or Right, Outstanding	401,446				401,446
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	117,535				117,535
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24				$ 4.24
Warrant Term					5 years
Class of Warrants or Rights, Exercises in Period	6,250						735
September 2014 Term Loan [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				58,962
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 4.24
Warrant Term				10 years
Amortization of Debt Discount (Premium)					$ 45,000	48,000
Unamortized Debt Issuance Expense	$ 342,000				342,000
Warrant [Member] | Vendors And Nonemployee [Member]
Allocated Share-based Compensation Expense					0	15,000
Warrant [Member] | Employees [Member]
Allocated Share-based Compensation Expense					0	244,000
Warrant [Member] | September 2014 Term Loan [Member]
Fair Value Assumptions, Expected Term			10 years
Vendors And Nonemployee [Member]
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period	625						5,157
September 2014 Term Loan [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			3,125	58,962
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.96	$ 4.24
Warrant Term			10 years	10 years
Amortization of Debt Discount (Premium)					0	0
Unamortized Debt Issuance Expense	$ 0				0	0
Allocated Share-based Compensation Expense					$ 188,000	$ 42,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	401,446				401,446				75,697	47,751
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 4	$ 4.24
Percent Of Outstanding Loan Amount	1.00%				1.00%

Note 7 - Common Stock - Summary

Note 7 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	3 Months Ended
	Mar. 31, 2016	Feb. 28, 2015	Nov. 30, 2014
Range One [Member]
Expiration Date	Sep. 23, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	110,550
Range Two [Member]
Expiration Date	Sep. 30, 2024
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	58,962
Range Three [Member]
Expiration Date	Oct. 13, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	29,000
Range Four [Member]
Expiration Date	Oct. 31, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	469
Range Five [Member]
Expiration Date	Nov. 12, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	12,500
Range Six [Member]
Expiration Date	Feb. 17, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	75,697
Range Seven [Member]
Expiration Date	Mar. 26, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.72
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,454
Range Eight [Member]
Expiration Date	May 12, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	36,229
Range Nine [Member]
Expiration Date	May 14, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.96
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	3,125
Range Ten [Member]
Expiration Date	May 17, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	21,585
Range Eleven [Member]
Expiration Date	Dec. 16, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	26,875
Range Twelve [Member]
Expiration Date	Mar. 31, 2026
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.08
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	401,446	75,697	47,751

Note 8 - Summary of Stock Opt33

Note 8 - Summary of Stock Options (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Jul. 22, 2015	Jul. 21, 2015
Two Thousand Five Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance	2,778
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,778
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 102.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 131 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	39,024
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 11.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 193 days
Conversion of Stock Exchange Ratio	0.0080497
Conversion of Stock, Post Revenue Stock Split Basis, Ratio	0.0010062
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	5 years
The 2013 Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance	130,918
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,089,966
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 6.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 131 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				1,262,500	388,949
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	129,267	79,375
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 3.56	$ 2
Employee Stock Option [Member]
Allocated Share-based Compensation Expense	$ 188,000	$ 42,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 2,598,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,131,768		1,022,195
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 6.42		$ 6.47
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 135 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	129,267
Allocated Share-based Compensation Expense	$ 188,000	42,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 2,000	$ 0

Note 8 - Summary of Stock Opt34

Note 8 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Options outstanding, beginning of period (in shares) | shares	1,022,195
Options outstanding, beginning of period (in dollars per share) | $ / shares	$ 6.47
Options outstanding, beginning of period	9 years 135 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	129,267
Options granted (in dollars per share) | $ / shares	$ 6.35
Options exercised (in shares) | shares	(1,314)
Options exercised (in dollars per share) | $ / shares	$ 4.80
Options canceled (in shares) | shares	(18,380)
Options canceled (in dollars per share) | $ / shares	$ 8.55
Options outstanding, end of period (in shares) | shares	1,131,768
Options outstanding, end of period (in dollars per share) | $ / shares	$ 6.42
Options outstanding, end of period | $	$ 414,727
Vested and exercisable and expected to vest, end of period, Number Of Shares (in shares) | shares	1,035,338
Vested and exercisable and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 6.48
Vested and exercisable and expected to vest, end of period, Weighted Average Remaining Contractual Term	9 years 80 days
Vested and exercisable and expected to vest, end of period, Aggregate Intrinsic Value | $	$ 392,137
Vested and exercisable, end of period, Number Of Shares (in shares) | shares	179,832
Vested and exercisable, end of period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 9.86
Vested and exercisable, end of period, Weighted Average Remaining Contractual Term	7 years 328 days
Vested and exercisable, end of period, Aggregate Intrinsic Value | $	$ 125,415

Note 8 - Summary of Options Out

Note 8 - Summary of Options Outstanding and Exercisable (Details)	Mar. 31, 2016$ / sharesshares
Range One [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 2.64
Options Outstanding Number Outstanding (in shares) | shares	12,500
Options Outstanding Weighted Average Remaining Contractual Term	9 years 43 days
Options Exercisable Number Exercisable (in shares) | shares
Options Exercisable Weighted Average Exercise Price (in dollars per share)
Range Two [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 3.75
Options Outstanding Number Outstanding (in shares) | shares	79,376
Options Outstanding Weighted Average Remaining Contractual Term	8 years 313 days
Options Exercisable Number Exercisable (in shares) | shares	21,498
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 3.75
Label 3 (in dollars per share)	3.68
Exercise Price Range - Upper Limit (in dollars per share)	3.76
Range Three [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 4.80
Options Outstanding Number Outstanding (in shares) | shares	212,300
Options Outstanding Weighted Average Remaining Contractual Term	8 years 156 days
Options Exercisable Number Exercisable (in shares) | shares	81,288
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 4.80
Range Four [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 6
Options Outstanding Number Outstanding (in shares) | shares	609,003
Options Outstanding Weighted Average Remaining Contractual Term	9 years 262 days
Options Exercisable Number Exercisable (in shares) | shares	29,599
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 6
Range Five [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 6.35
Options Outstanding Number Outstanding (in shares) | shares	129,267
Options Outstanding Weighted Average Remaining Contractual Term	9 years 332 days
Options Exercisable Number Exercisable (in shares) | shares
Options Exercisable Weighted Average Exercise Price (in dollars per share)
Label 3 (in dollars per share)	$ 6.24
Exercise Price Range - Upper Limit (in dollars per share)	6.40
Range Six [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 7.67
Options Outstanding Number Outstanding (in shares) | shares	41,875
Options Outstanding Weighted Average Remaining Contractual Term	9 years 127 days
Options Exercisable Number Exercisable (in shares) | shares
Options Exercisable Weighted Average Exercise Price (in dollars per share)
Label 3 (in dollars per share)	$ 7.12
Exercise Price Range - Upper Limit (in dollars per share)	7.92
Range Seven [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 9.92
Options Outstanding Number Outstanding (in shares) | shares	38,429
Options Outstanding Weighted Average Remaining Contractual Term	6 years 215 days
Options Exercisable Number Exercisable (in shares) | shares	38,429
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 9.92
Range Eight [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 69.63
Options Outstanding Number Outstanding (in shares) | shares	6,810
Options Outstanding Weighted Average Remaining Contractual Term	1 year 153 days
Options Exercisable Number Exercisable (in shares) | shares	6,810
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 69.63
Label 3 (in dollars per share)	56
Exercise Price Range - Upper Limit (in dollars per share)	72
Range Nine [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 119.53
Options Outstanding Number Outstanding (in shares) | shares	2,176
Options Outstanding Weighted Average Remaining Contractual Term	1 year 178 days
Options Exercisable Number Exercisable (in shares) | shares	2,176
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 119.53
Label 3 (in dollars per share)	96
Exercise Price Range - Upper Limit (in dollars per share)	149.04
Range Ten [Member]
Exercise Price Range - Weighted Average (in dollars per share)	$ 296
Options Outstanding Number Outstanding (in shares) | shares	32
Options Outstanding Weighted Average Remaining Contractual Term	1 year 175 days
Options Exercisable Number Exercisable (in shares) | shares	32
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 296
Exercise Price Range - Weighted Average (in dollars per share)	$ 6.42
Options Outstanding Number Outstanding (in shares) | shares	1,131,768
Options Outstanding Weighted Average Remaining Contractual Term	9 years 87 days
Options Exercisable Number Exercisable (in shares) | shares	179,832
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 9.86

Note 8 - Summary of Stock Opt36

Note 8 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Expected term (in years)	5 years	5 years
Average volatility	66.00%	62.00%
Risk-free interest rate	1.55%	1.32%
Dividend yield	0.00%	0.00%

Note 8 - Summary of Stock Opt37

Note 8 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	$ 21	$ 4
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	167	38
Allocated Share-based Compensation Expense	$ 188	$ 42

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Effective Income Tax Rate Reconciliation, Percent	0.00%	0.00%

Note 10 - Related Party Trans39

Note 10 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	Oct. 04, 2007	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Stock Issued During Period, Shares, New Issues	37,500
Right to Repurchase Stock Term				4 years
Related Party Transaction, Amounts of Transaction		$ 1,215,000	$ 129,000

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual)	Apr. 15, 2016
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	8